Sign In
Buy VRNA
$106.91
+0 (+0%)
At Close: Jan 06, 2026
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD
04:01pm, Monday, 19'th Dec 2022
LONDON and RALEIGH, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory d
Here's Why Verona Pharma PLC American Depositary Share (VRNA) is a Great Momentum Stock to Buy
01:33pm, Monday, 05'th Dec 2022
Does Verona Pharma PLC American Depositary Share (VRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Momentum in Verona Pharma PLC American Depositary Share (VRNA) Should Keep going
10:32am, Tuesday, 15'th Nov 2022
Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the ma
Verona Pharma plc (VRNA) Q3 2022 Earnings Call Transcript
02:04pm, Wednesday, 09'th Nov 2022
Verona Pharma plc (NASDAQ:VRNA ) Q3 2022 Earnings Conference Call November 9, 2022 9:00 AM ET Company Participants David Zaccardelli – Chief Executive Officer Mark Hahn – Chief Financial Officer K
Verona Pharma Announces November 2022 Investor Conference Participation
03:00am, Wednesday, 02'nd Nov 2022
LONDON and RALEIGH, N.C., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will participate in the follow
3 Small-Cap Pharma Stocks For A 2022 Melt-Up
12:00pm, Thursday, 27'th Oct 2022
This year's bear markets have resulted in a fall in portfolio performance. Healthcare, the second best sector this year, is defensive and has stood the test of time. The Fed's stance and volatile pric
Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update
02:00am, Wednesday, 26'th Oct 2022
LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respirato
Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point
05:02am, Tuesday, 13'th Sep 2022
Verona achieved primary and secondary endpoints in phase 3 ENHANCE-2 study using ensifentrine as maintenance treatment of COPD. Results from the second phase 3 study, ENHANCE-1, also using ensifentrin
Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
02:00am, Monday, 29'th Aug 2022
LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overvie
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
07:52am, Wednesday, 10'th Aug 2022 Benzinga
Gainers
AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.
BBQ Holdings, Inc. (NAS
Dow Drops Over 100 Points; Verona Pharma Shares Jump
07:11pm, Tuesday, 09'th Aug 2022 Benzinga
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 100 points on Tuesday.
The Dow traded down 0.34% to 32,720.07 while the NASDAQ fell 1.38% to 12,470.08. The S&
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
05:26pm, Tuesday, 09'th Aug 2022 Benzinga
Gainers
Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for CO
Nasdaq Tumbles 1.5%; BBQ Holdings Shares Spike Higher
05:01pm, Tuesday, 09'th Aug 2022 Benzinga
U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 1.5% on Tuesday.
The Dow traded down 0.12% to 32,794.11 while the NASDAQ fell 1.54% to 12,450.29. The S&P also fell, dr
All You Need to Know About Verona Pharma PLC American Depositary Share (VRNA) Rating Upgrade to Strong Buy
04:00pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Verona Pharma PLC American Depositary Share (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Why Verona Pharma Stock Is Skyrocketing Today
03:52pm, Tuesday, 09'th Aug 2022 The Motley Fool
The company reported overwhelmingly positive results from a late-stage study of its COPD drug candidate.
